Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.62 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | PTPRA | P18433 | 1/20 | 0.62 |
| ▸ | PTPRB | P23467 | 1/20 | 0.62 |
| ▸ | PTPRE | P23469 | 1/20 | 0.62 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307027 | 0.85 | PTPRC (0.59) | PTPRCPTPN2PTPN1PTPRAPTPRB | |
| SCHEMBL1309690 | 0.85 | PTPRC (0.59) | PTPRCPTPN2PTPN1PTPRAPTPRB | |
| SCHEMBL1308617 | 0.85 | PTPRC (0.59) | PTPRCPTPN2PTPN1PTPRAPTPRB | |
| SCHEMBL1310012 | 0.85 | AKR1C2 (0.60) | MEN1KMT2ATDP1GFERMAPT | |
| SCHEMBL1309941 | 0.85 | SERPINE1 (0.65) | MEN1KMT2ATDP1CA12CA7 | |
| SCHEMBL1308363 | 0.85 | CYP1A2 (0.59) | PTPRCPTPN2PTPN1PTPRAPTPRB | |
| SCHEMBL14075414 | 0.84 | MEN1 (0.70) | PTPRCPTPN2PTPN1PTPRAPTPRB | |
| SCHEMBL14075294 | 0.84 | LTC4S (0.72) | PTPRCPTPN2PTPN1PTPRAPTPRB | |
| SCHEMBL1310079 | 0.82 | GFER (0.78) | PTPRCPTPN2PTPN1PTPRAPTPRB | |
| SCHEMBL1307975 | 0.81 | MEN1 (0.60) | PTPRCPTPN2PTPN1PTPRAPTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| EP-1940792-A2 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES INHIBITORS OF PIM-1 AND/OR PIM-3 | Exelixis, Inc. (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2007044724-A2 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES INHIBITORS OF PIM-I AND/OR PIM-3 | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| WO-2004022525-A1 | AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | claimed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2004022525-A1 | AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | PIM1, PIM3, PIM2 | PTPRC 203/4885PTPN2 284/4885PTPN1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.